Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of mycobacterium tuberculosis

Jozef Stec, Catherine Vilchèze, Shichun Lun, Alexander L. Perryman, Xin Wang, Joel S. Freundlich, William Bishai, William R. Jacobs, Alan P. Kozikowski

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

New triclosan (TRC) analogues were evaluated for their activity against the enoyl-acyl carrier protein reductase InhA in Mycobacterium tuberculosis (Mtb). TRC is a well-known inhibitor of InhA, and specific modifications to its positions 5 and 4' afforded 27 derivatives; of these compounds, seven derivatives showed improved potency over that of TRC. These analogues were active against both drug-susceptible and drug-resistant Mtb strains. The most active compound in this series, 4-(n-butyl)-1,2,3-triazolyl TRC derivative 3, had an MIC value of 0.6 μg mL-1 (1.5 μM) against wild-type Mtb. At a concentration equal to its MIC, this compound inhibited purified InhA by 98 %, and showed an IC50 value of 90 nM. Compound 3 and the 5-methylisoxazole-modified TRC 14 were able to inhibit the biosynthesis of mycolic acids. Furthermore, mc24914, an Mtb strain overexpressing inhA, was found to be less susceptible to compounds 3 and 14, supporting the notion that InhA is the likely molecular target of the TRC derivatives presented herein.

Original languageEnglish (US)
Pages (from-to)2528-2537
Number of pages10
JournalChemMedChem
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Triclosan
Acyl Carrier Protein
Mycobacterium tuberculosis
Oxidoreductases
Pharmaceutical Preparations
Derivatives
Mycolic Acids
Multidrug-Resistant Tuberculosis
Biosynthesis
Inhibitory Concentration 50

Keywords

  • enoyl reductase
  • molecular docking
  • Mycobacterium tuberculosis
  • mycolic acid
  • triclosan scaffold

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of mycobacterium tuberculosis. / Stec, Jozef; Vilchèze, Catherine; Lun, Shichun; Perryman, Alexander L.; Wang, Xin; Freundlich, Joel S.; Bishai, William; Jacobs, William R.; Kozikowski, Alan P.

In: ChemMedChem, Vol. 9, No. 11, 01.11.2014, p. 2528-2537.

Research output: Contribution to journalArticle

Stec, Jozef ; Vilchèze, Catherine ; Lun, Shichun ; Perryman, Alexander L. ; Wang, Xin ; Freundlich, Joel S. ; Bishai, William ; Jacobs, William R. ; Kozikowski, Alan P. / Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of mycobacterium tuberculosis. In: ChemMedChem. 2014 ; Vol. 9, No. 11. pp. 2528-2537.
@article{e0d8b8fb728d405584a15481526948b8,
title = "Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of mycobacterium tuberculosis",
abstract = "New triclosan (TRC) analogues were evaluated for their activity against the enoyl-acyl carrier protein reductase InhA in Mycobacterium tuberculosis (Mtb). TRC is a well-known inhibitor of InhA, and specific modifications to its positions 5 and 4' afforded 27 derivatives; of these compounds, seven derivatives showed improved potency over that of TRC. These analogues were active against both drug-susceptible and drug-resistant Mtb strains. The most active compound in this series, 4-(n-butyl)-1,2,3-triazolyl TRC derivative 3, had an MIC value of 0.6 μg mL-1 (1.5 μM) against wild-type Mtb. At a concentration equal to its MIC, this compound inhibited purified InhA by 98 {\%}, and showed an IC50 value of 90 nM. Compound 3 and the 5-methylisoxazole-modified TRC 14 were able to inhibit the biosynthesis of mycolic acids. Furthermore, mc24914, an Mtb strain overexpressing inhA, was found to be less susceptible to compounds 3 and 14, supporting the notion that InhA is the likely molecular target of the TRC derivatives presented herein.",
keywords = "enoyl reductase, molecular docking, Mycobacterium tuberculosis, mycolic acid, triclosan scaffold",
author = "Jozef Stec and Catherine Vilch{\`e}ze and Shichun Lun and Perryman, {Alexander L.} and Xin Wang and Freundlich, {Joel S.} and William Bishai and Jacobs, {William R.} and Kozikowski, {Alan P.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/cmdc.201402255",
language = "English (US)",
volume = "9",
pages = "2528--2537",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of mycobacterium tuberculosis

AU - Stec, Jozef

AU - Vilchèze, Catherine

AU - Lun, Shichun

AU - Perryman, Alexander L.

AU - Wang, Xin

AU - Freundlich, Joel S.

AU - Bishai, William

AU - Jacobs, William R.

AU - Kozikowski, Alan P.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - New triclosan (TRC) analogues were evaluated for their activity against the enoyl-acyl carrier protein reductase InhA in Mycobacterium tuberculosis (Mtb). TRC is a well-known inhibitor of InhA, and specific modifications to its positions 5 and 4' afforded 27 derivatives; of these compounds, seven derivatives showed improved potency over that of TRC. These analogues were active against both drug-susceptible and drug-resistant Mtb strains. The most active compound in this series, 4-(n-butyl)-1,2,3-triazolyl TRC derivative 3, had an MIC value of 0.6 μg mL-1 (1.5 μM) against wild-type Mtb. At a concentration equal to its MIC, this compound inhibited purified InhA by 98 %, and showed an IC50 value of 90 nM. Compound 3 and the 5-methylisoxazole-modified TRC 14 were able to inhibit the biosynthesis of mycolic acids. Furthermore, mc24914, an Mtb strain overexpressing inhA, was found to be less susceptible to compounds 3 and 14, supporting the notion that InhA is the likely molecular target of the TRC derivatives presented herein.

AB - New triclosan (TRC) analogues were evaluated for their activity against the enoyl-acyl carrier protein reductase InhA in Mycobacterium tuberculosis (Mtb). TRC is a well-known inhibitor of InhA, and specific modifications to its positions 5 and 4' afforded 27 derivatives; of these compounds, seven derivatives showed improved potency over that of TRC. These analogues were active against both drug-susceptible and drug-resistant Mtb strains. The most active compound in this series, 4-(n-butyl)-1,2,3-triazolyl TRC derivative 3, had an MIC value of 0.6 μg mL-1 (1.5 μM) against wild-type Mtb. At a concentration equal to its MIC, this compound inhibited purified InhA by 98 %, and showed an IC50 value of 90 nM. Compound 3 and the 5-methylisoxazole-modified TRC 14 were able to inhibit the biosynthesis of mycolic acids. Furthermore, mc24914, an Mtb strain overexpressing inhA, was found to be less susceptible to compounds 3 and 14, supporting the notion that InhA is the likely molecular target of the TRC derivatives presented herein.

KW - enoyl reductase

KW - molecular docking

KW - Mycobacterium tuberculosis

KW - mycolic acid

KW - triclosan scaffold

UR - http://www.scopus.com/inward/record.url?scp=84927164561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927164561&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201402255

DO - 10.1002/cmdc.201402255

M3 - Article

C2 - 25165007

AN - SCOPUS:84927164561

VL - 9

SP - 2528

EP - 2537

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 11

ER -